FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808375489> ?p ?o ?g. }

• W2808375489 abstract "Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objective response rate and long median survival after treatment. However, complete remission is almost never achieved. The liver is the most commonly affected organ in metastatic disease and is the most incriminating factor for patient survival. Additional treatment of liver disease after PRRT may improve outcome in NET patients. Radioembolization is an established therapy for liver metastasis. To investigate this hypothesis, a phase 2 study was initiated to assess effectiveness and toxicity of holmium-166 radioembolization (166Ho-RE) after PRRT with lutetium-177 (177Lu)-DOTATATE. The HEPAR PLUS trial (“Holmium Embolization Particles for Arterial Radiotherapy Plus 177 Lu-DOTATATE in Salvage NET patients”) is a single centre, interventional, non-randomized, non-comparative, open label study. In this phase 2 study 30–48 patients with > 3 measurable liver metastases according to RECIST 1.1 will receive additional 166Ho-RE within 20 weeks after the 4th and last cycle of PRRT with 7.4 GBq 177Lu-DOTATATE. Primary objectives are to assess tumour response, complete and partial response according to RECIST 1.1, and toxicity, based on CTCAE v4.03, 3 months after 166Ho-RE. Secondary endpoints include biochemical response, quality of life, biodistribution and dosimetry. This is the first prospective study to combine PRRT with 177Lu-DOTATATE and additional 166Ho-RE in metastatic NET. A radiation boost on intrahepatic disease using 166Ho-RE may lead to an improved response rate without significant additional side-effects. Clinicaltrials.gov NCT02067988 , 13 February 2014. Protocol version: 6, 30 november 2016." @default.
• W2808375489 created "2018-06-21" @default.
• W2808375489 creator A5005933856 @default.
• W2808375489 creator A5012997419 @default.
• W2808375489 creator A5023302477 @default.
• W2808375489 creator A5025180096 @default.
• W2808375489 creator A5027533181 @default.
• W2808375489 creator A5030843436 @default.
• W2808375489 creator A5031392540 @default.
• W2808375489 creator A5035775899 @default.
• W2808375489 creator A5048261461 @default.
• W2808375489 creator A5051038749 @default.
• W2808375489 creator A5081803376 @default.
• W2808375489 date "2018-06-15" @default.
• W2808375489 modified "2023-10-09" @default.
• W2808375489 title "Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)" @default.
• W2808375489 cites W1495055668 @default.
• W2808375489 cites W1532334298 @default.
• W2808375489 cites W1603744955 @default.
• W2808375489 cites W1973890922 @default.
• W2808375489 cites W1979065577 @default.
• W2808375489 cites W1981002414 @default.
• W2808375489 cites W1984882652 @default.
• W2808375489 cites W1994022899 @default.
• W2808375489 cites W2004740412 @default.
• W2808375489 cites W2006821285 @default.
• W2808375489 cites W2009629472 @default.
• W2808375489 cites W2016285888 @default.
• W2808375489 cites W2018476933 @default.
• W2808375489 cites W2019746157 @default.
• W2808375489 cites W2028793063 @default.
• W2808375489 cites W2034720182 @default.
• W2808375489 cites W2051842222 @default.
• W2808375489 cites W2052148672 @default.
• W2808375489 cites W2057893200 @default.
• W2808375489 cites W2076032405 @default.
• W2808375489 cites W2078072232 @default.
• W2808375489 cites W2080519663 @default.
• W2808375489 cites W2082204604 @default.
• W2808375489 cites W2087394476 @default.
• W2808375489 cites W2100283328 @default.
• W2808375489 cites W2107276199 @default.
• W2808375489 cites W2115127415 @default.
• W2808375489 cites W2125398839 @default.
• W2808375489 cites W2126616257 @default.
• W2808375489 cites W2128267006 @default.
• W2808375489 cites W2130932024 @default.
• W2808375489 cites W2135503195 @default.
• W2808375489 cites W2137142564 @default.
• W2808375489 cites W2148524882 @default.
• W2808375489 cites W2148933046 @default.
• W2808375489 cites W2149214723 @default.
• W2808375489 cites W2166106543 @default.
• W2808375489 cites W2166305638 @default.
• W2808375489 cites W2170707038 @default.
• W2808375489 cites W2253652599 @default.
• W2808375489 cites W2754222236 @default.
• W2808375489 cites W278682861 @default.
• W2808375489 cites W4254158343 @default.
• W2808375489 doi "https://doi.org/10.1186/s12876-018-0817-8" @default.
• W2808375489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6003090" @default.
• W2808375489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29902988" @default.
• W2808375489 hasPublicationYear "2018" @default.
• W2808375489 type Work @default.
• W2808375489 sameAs 2808375489 @default.
• W2808375489 citedByCount "30" @default.
• W2808375489 countsByYear W28083754892019 @default.
• W2808375489 countsByYear W28083754892020 @default.
• W2808375489 countsByYear W28083754892021 @default.
• W2808375489 countsByYear W28083754892022 @default.
• W2808375489 countsByYear W28083754892023 @default.
• W2808375489 crossrefType "journal-article" @default.
• W2808375489 hasAuthorship W2808375489A5005933856 @default.
• W2808375489 hasAuthorship W2808375489A5012997419 @default.
• W2808375489 hasAuthorship W2808375489A5023302477 @default.
• W2808375489 hasAuthorship W2808375489A5025180096 @default.
• W2808375489 hasAuthorship W2808375489A5027533181 @default.
• W2808375489 hasAuthorship W2808375489A5030843436 @default.
• W2808375489 hasAuthorship W2808375489A5031392540 @default.
• W2808375489 hasAuthorship W2808375489A5035775899 @default.
• W2808375489 hasAuthorship W2808375489A5048261461 @default.
• W2808375489 hasAuthorship W2808375489A5051038749 @default.
• W2808375489 hasAuthorship W2808375489A5081803376 @default.
• W2808375489 hasBestOaLocation W28083754891 @default.
• W2808375489 hasConcept C126322002 @default.
• W2808375489 hasConcept C126838900 @default.
• W2808375489 hasConcept C143998085 @default.
• W2808375489 hasConcept C2776694085 @default.
• W2808375489 hasConcept C2778019345 @default.
• W2808375489 hasConcept C2779066768 @default.
• W2808375489 hasConcept C2779185275 @default.
• W2808375489 hasConcept C2779984678 @default.
• W2808375489 hasConcept C2780739268 @default.
• W2808375489 hasConcept C2989005 @default.
• W2808375489 hasConcept C2993559085 @default.
• W2808375489 hasConcept C31760486 @default.
• W2808375489 hasConcept C535046627 @default.
• W2808375489 hasConcept C71924100 @default.
• W2808375489 hasConceptScore W2808375489C126322002 @default.
• W2808375489 hasConceptScore W2808375489C126838900 @default.

• next